TY - JOUR
T1 - Recurrent neonatal herpes simplex virus infection with central nervous system disease after completion of a 6-month course of suppressive therapy
T2 - Case report
AU - Kato, Koji
AU - Hara, Shinya
AU - Kawada, Jun ichi
AU - Ito, Yoshinori
N1 - Publisher Copyright:
© 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - A boy at 12 days of age developed neonatal herpes simplex virus (HSV) type 2 infection with central nervous system (CNS) disease. After a 21-day course of high-dose intravenous acyclovir, the patient recovered with negative results for HSV DNA in serum and cerebrospinal fluid. Two weeks after a 6-month course of oral valacyclovir suppressive therapy with negative virological assessment, the disease recurred. Another 21-day course of intravenous acyclovir and subsequent 1-year course of oral suppressive therapy were completed. He showed mild developmental delay in language-social skills at 18 months of age. Although recurrences of neonatal HSV infection with CNS disease after suppressive therapy are uncommon, both clinical and virological assessments at the end of the suppressive therapy may be required. Administration of extended long-term suppressive ACV therapy should be considered to reduce the rate of recurrence.
AB - A boy at 12 days of age developed neonatal herpes simplex virus (HSV) type 2 infection with central nervous system (CNS) disease. After a 21-day course of high-dose intravenous acyclovir, the patient recovered with negative results for HSV DNA in serum and cerebrospinal fluid. Two weeks after a 6-month course of oral valacyclovir suppressive therapy with negative virological assessment, the disease recurred. Another 21-day course of intravenous acyclovir and subsequent 1-year course of oral suppressive therapy were completed. He showed mild developmental delay in language-social skills at 18 months of age. Although recurrences of neonatal HSV infection with CNS disease after suppressive therapy are uncommon, both clinical and virological assessments at the end of the suppressive therapy may be required. Administration of extended long-term suppressive ACV therapy should be considered to reduce the rate of recurrence.
UR - http://www.scopus.com/inward/record.url?scp=84947493186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947493186&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2015.08.005
DO - 10.1016/j.jiac.2015.08.005
M3 - Article
C2 - 26390826
AN - SCOPUS:84947493186
SN - 1341-321X
VL - 21
SP - 879
EP - 881
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 12
ER -